Genmab — August 2016
-
+1,10%.
-
mon vi slutter over 1200 i dag?
-
are you aware of any filing plans for subcut in 2017? We are not aware of any filing plans in 2017. What I understand for the subcu daratumumab work is going very well, as I already said in my answer to chance question. But I understand up until this phone call actually, is that there will be a new Phase III trial needed to get the new drug, because it's a new drug formulated at the Halozyme enzyme for subcutaneous application, and that one large Phase III trial is needed to get it approved wor
-
ok - det lugter af, at 1st line sc også skal igennem fase 3. Størrelsen af fase 1 med 700 patienter må være for at kunne gå direkte i fase 3
-
Euroinvestors debat.
-
Derfra henter pressen ofte de "harmdirrende" kommentarer.
-
Fred være med det. Der er plads nok på nettet.
-
Millionærklubben vinklede den flot i morges. Lau han forklarede præcis det som Jan van de Winkel fortæller i Børsen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind